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for a recurrent episode of depression after smoking ces-
sation (12). Models describing the relationship between 
symptoms of depression and cigarette smoking include 
examples of shared genetic risk (13). We carried out genet-
ic linkage analyses of DSM-IV-diagnosed major depressive 
disorder in two samples that are part of the Nicotine Ad-
diction Genetics project (14, 15), an international consor-
tium focused on tobacco dependence. We used an affected 
sibling-pair design, in which at least two adult offspring 
per family reported a history of DSM-IV major depressive 
disorder, and tested for linkage. Results appear to confirm 
a genome-wide significant linkage signal at chromosome 
3p26-3p25, also reported in an independent linkage study 
of major depressive disorder conducted by Breen et al. (16).
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Objective: The authors tested for ge-
netic linkage of DSM-IV-diagnosed major 
depressive disorder in families that were 
ascertained for cigarette smoking.
Method: W ithin a study that targeted 
families characterized by a history of 
smoking, analyses derived a subset of 
91 Australian families with two or more 
offspring with a history of DSM-IV major 
depressive disorder (affected sibling pairs, 
N=187) and 25 Finnish families (affected 
sibling pairs, N=33). W ithin this affected 
sibling pairs design, the authors conduct-
ed nonparametric linkage analysis.
Results: In the Australian heavy smoking 
families, the authors found a genome-
wide significant multipoint LOD score of 
4.14 for major depressive disorder on 
chromosome 3 at 24.9 cM (3p26-3p25).
Conclusions: Genome-wide significant 
linkage was detected for major depressive 
disorder on chromosome 3p in a sample 
ascertained for smoking. A linkage peak 
at this location was also observed in an 
independent study of major depressive 
disorder.
Genetic linkage studies of major depressive disorder 
have found suggestive evidence across multiple genomic 
regions but with little convergence of findings (1). Genetic 
association findings, including those from genome-wide 
association studies (GWASs), have been similarly disparate 
(2–7). These inconsistencies raise the question of wheth-
er major depressive disorder encompasses a number of 
poorly understood subtypes (e.g., depression in smokers). 
Among cigarette smokers seeking cessation treatment, 
lifetime rates of major depression have been estimated 
at over 60% (8). Cigarette smokers with a history of de-
pression tend to report more severe nicotine withdrawal 
symptoms (9–11), are more likely to relapse to smoking 
after an attempt to quit (8), and may be at increased risk 
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plete report of these single- and multipoint findings, along 
with marker positions by chromosome, is provided in Ta-
ble 2 of the data supplement. The addition of 290 SNPs on 
chromosome 3 narrowed the linkage locus and increased 
the LOD score to 4.55 (at 25.3 cM) (Figure 1). For the Finn-
ish major depressive disorder sample, a multipoint LOD 
score of 2.10 was found on chromosome 20 (at 90.9 cM).
Given that no linkage signals greater than 1.5 overlapped 
across both samples, we did not conduct a combined 
analysis. However, if we were to correct conservatively for 
testing in both samples by doubling the p value generated 
from the 1,000 simulations, we would still maintain a ge-
nome-wide significant p value of 0.008.
d iscu ssion
Overall, major depressive disorder was associated with 
a significant genetic linkage peak (a LOD score of 4.14) on 
chromosome 3 in the Nicotine Addiction Genetics Austra-
lian sample, replicating the linkage reported at the same 
location by Breen et al. (16). These converging findings 
suggest that the genomic region spanning across 3p26-
3p25 is an important area for further investigation in ge-
netic research on major depressive disorder. Given the 
small number of Finnish affected sibling pairs, the lack of 
confirmation in this particular sample is not unexpected. 
The genetic variants accounting for this linkage signal 
have not yet been convincingly identified. Although our 
highest single-point microsatellite marker (D3S1304 [LOD 
score=3.7]) lies within the metabotropic glutamate recep-
tor 7 gene (GRM7), subsidiary association analyses within 
a one-LOD support interval, using GWAS data available in 
the Australian sample (28), found only nominal associa-
tion for two SNPs within GRM7 (p<0.05). Even our stron-
gest association effect, which was a p value of 0.00014 for 
rs6765537 (a nonsynonymous SNP within C3or20 at 33.87 
cM), did not replicate in the Finnish families, nor did it 
replicate in the Genetic Association Information Network 
major depressive disorder sample from the Netherlands 
(2, 30). Thus, while others have found suggestive associa-
tion between SNPs in GRM7 and major depressive disor-
der (7, 31), genome-wide significant effects have not been 
reported. Further, because linkage implicates very broad 
regions, GRM7 is among many genes that might be hy-
pothesized to explain our signal.
In terms of other linkage findings, one for quantity 
smoked in samples ascertained for depression has been 
reported near our chromosome 3 finding for major de-
pressive disorder (32), raising the possibility of common 
genetic influences across major depressive disorder and 
smoking-related behavior or of gene-by-environment (i.e., 
smoking) interaction effects on major depressive disorder.
There are important limitations associated with our re-
sults. Our sample of 91 families is small by standards of 
modern genomic efforts. Thus, we cannot exclude the 
possibility that our finding is a false positive that coin-
M ethod
Samples
The Nicotine Addiction Genetics linkage project enrolled 
participants at the Queensland Institute of Medical Research in 
Australia and the University of Helsinki in Finland. Both sites uti-
lized twin registries and targeted families of index cases with a 
previously reported history of cigarette smoking in interview or 
questionnaire surveys; the Australian site used a higher thresh-
old measure when recruiting index cases with a history of heavy 
smoking (14). These original linkage samples included micro-
satellite marker data and telephone diagnostic interviews for 
289 families from the Australian site (offspring, N=917; parents, 
N=392) and 161 families from the Finnish site (offspring, N=522; 
parents, N=19). More than 90% of the participants from the Aus-
tralian site were of Anglo-Celtic or Northern European ancestry, 
and all of the participants from the Finnish site were of Finnish 
ancestry. The assessment included a diagnostic telephone inter-
view, adapted from the Semi-Structured Assessment for the Ge-
netics of Alcoholism (17, 18), which obtained a comprehensive 
evaluation of lifetime DSM-IV (19) major depressive disorder as 
well as a tobacco use and dependence assessment derived from 
the Composite International Diagnostic Interview (20). Addi-
tional details on the original samples and assessments have been 
described elsewhere (14, 15, 21). For the present study, we con-
ducted genetic linkage analyses using the 91 Australian families 
who had one or more affected sibling pairs concordant for a his-
tory of major depressive disorder (N=187). In the Finnish sample, 
only 25 families had one or more affected sibling pairs (N=33), 
and thus the primary analyses focused on the Australian sample. 
A summary of the two major depressive disorder linkage samples 
is presented in Table 1 of the data supplement accompanying the 
online version of this article.
Analyses
For both the Australian and Finnish samples, 381 autosomal 
microsatellite markers were genotyped and spaced at approxi-
mately 10 cM across the genome, positioned using the deCODE 
Genetics (Reykjavik, Iceland) map (22). Details of genotyping, in-
cluding quality control procedures, are described elsewhere (14, 
15). Single- and multipoint affected sibling pair nonparametric 
linkage (the latter using a 2-cM grid) was conducted in MERLIN 
(Multipoint Engine for Rapid Likelihood Inference [23]), which 
generated LOD scores (24, 25). Upon detection of LOD scores >3, 
genome-wide corrected p values were calculated from 1,000 rep-
licates simulated in MERLIN (26, 27).
Follow-up fine mapping included the addition of 290 single 
nucleotide polymorphisms (SNPs) on chromosome 3 that were 
available for a portion of the Australian major depressive disorder 
linkage sample (84 out of 91 families), from other Australian proj-
ects with overlapping samples that obtained GWAS data (see ref-
erence 28). Through the use of Snagger software (29), these SNPs 
were selected to be in low linkage disequilibrium (maximum pair-
wise r2=0.2), to have a minor allele frequency >40%, and to have 
a minimum distance between two tags of 450 kb in order to opti-
mize information content.
Resu lts
For the Australian linkage sample, a multipoint LOD 
score of 4.14 for major depressive disorder was found 
on chromosome 3 (at 24.9 cM). The highest single-point 
linkage signal emerged at microsatellite marker D3S1304, 
with a LOD score of 3.7. The LOD score of 4.14 at 3p in this 
sample met genome-wide significance (p=0.004). A com-
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